ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för volasertib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

33 träffar

Bibliografisk träff 2024-02-23

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.

Sarkar S, Chanda A, Khanolkar RA, Lambie M, Ailles L, Bratman SV, Narendran A, Bose P.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines12030503

Bibliografisk träff 2024-01-02

Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.

Yousef EH, El-Mesery ME, Habeeb MR, Eissa LA.

Naunyn Schmiedebergs Arch Pharmacol · journal article · DOI 10.1007/s00210-023-02894-8

Bibliografisk träff 2023-09-15

Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies.

El-Kalyoubi S, El-Sebaey SA, Elfeky SM, Al-Ghulikah HA, El-Zoghbi MS.

Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph16091303

Bibliografisk träff 2023-07-08

BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.

Riantana H, Waenphimai O, Mahalapbutr P, Karnchanapandh K, Vaeteewoottacharn K, Wongkham S, Sawanyawisuth K.

Pathol Res Pract · journal article · DOI 10.1016/j.prp.2023.154678

Bibliografisk träff 2023-02-09

Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis.

Wei X, Song M, Huang C, Yu Q, Jiang G, Jin G, Jia X, Shi Z.

Front Oncol · systematic review; systematic-review; journal article · DOI 10.3389/fonc.2023.1062885

Bibliografisk träff 2022-11-25

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts.

Passeri T, Dahmani A, Masliah-Planchon J, El Botty R, Courtois L, Vacher S, Marangoni E, Nemati F, Roman-Roman S, Adle-Biassette H, Mammar H, Froelich S, Bièche I, Decaudin D.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2022.960720

Bibliografisk träff 2022-11-16

Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells.

Choi EJ, Koo BK, Hur EH, Moon JH, Kim JY, Park HS, Choi Y, Lee KH, Lee JH, Choi EK, Lee JH.

Biomol Ther (Seoul) · research-article; journal article · DOI 10.4062/biomolther.2022.117

Bibliografisk träff 2022-09-01

BI6727, a polo-like kinase 1 inhibitor, synergizes with gefitinib to suppress hepatocellular carcinoma cells via a G2/M arrest mechanism.

Zhou Q, Chen T.

Pharmazie · research support, non-u.s. gov't; journal article · DOI 10.1691/ph.2022.2392

Bibliografisk träff 2022-05-21

Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.

Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U.

BMC Cancer · research-article; journal article · DOI 10.1186/s12885-022-09622-0

Bibliografisk träff 2022-05-20

Shedding light on the binding mechanism of kinase inhibitors BI-2536, Volasetib and Ro-3280 with their pharmacological target PLK1.

Fernández-Sainz J, Pacheco-Liñán PJ, Granadino-Roldán JM, Bravo I, Rubio-Martínez J, Albaladejo J, Garzón-Ruiz A.

J Photochem Photobiol B · journal article · DOI 10.1016/j.jphotobiol.2022.112477

Bibliografisk träff 2021-10-28

Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.

Karim RM, Bikowitz MJ, Chan A, Zhu JY, Grassie D, Becker A, Berndt N, Gunawan S, Lawrence NJ, Schönbrunn E.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.1c01096

Bibliografisk träff 2021-08-02

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.

Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim HJ, Lee JH, Usuki K, D'Ardia S, Won Jung C, Salamero O, Horst HA, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo DJ, Naoe T, Sekeres MA, Belsack V, Ge M, Taube T, Ottmann OG.

Hemasphere · research-article; journal article · DOI 10.1097/hs9.0000000000000617

Bibliografisk träff 2021-07-01

Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.

Goroshchuk O, Kolosenko I, Kunold E, Vidarsdottir L, Pirmoradian M, Azimi A, Jafari R, Palm-Apergi C.

FASEB J · research support, non-u.s. gov't; journal article · DOI 10.1096/fj.202100457rr

Bibliografisk träff 2021-05-01

Pharmacological inhibition of PI5P4Kα/β disrupts cell energy metabolism and selectively kills p53-null tumor cells.

Chen S, Chandra Tjin C, Gao X, Xue Y, Jiao H, Zhang R, Wu M, He Z, Ellman J, Ha Y.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.2002486118

Bibliografisk träff 2021-02-06

α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer.

Wang Z, Zhao S, Gu W, Dong Y, Meng F, Yuan J, Zhong Z.

Acta Biomater · research support, non-u.s. gov't; journal article · DOI 10.1016/j.actbio.2021.02.007

Bibliografisk träff 2020-11-01

Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors.

Lang I, Liu D, Fritsch H, Taube T, Chizhikov E, Liptai B.

Clin Ther · clinical trial, phase i; journal article · DOI 10.1016/j.clinthera.2020.09.015

Bibliografisk träff 2020-09-20

Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.

Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL.

Int J Hematol · clinical trial, phase i; journal article · DOI 10.1007/s12185-020-02994-8

Bibliografisk träff 2020-05-01

BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.

Chen E, Pei R.

J Int Med Res · research-article; journal article · DOI 10.1177/0300060520926093

Bibliografisk träff 2020-05-01

Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo [Retraction].

Författaruppgift saknas

Am J Cancer Res · retraction of publication; journal article; retraction notice

Bibliografisk träff 2019-11-05

Volasertib preclinical activity in high-risk hepatoblastoma.

Kats D, Ricker CA, Berlow NE, Noblet B, Nicolle D, Mevel K, Branchereau S, Judde JG, Stiverson CD, Stiverson CL, Svalina MN, Settelmeyer T, Matlock K, Lathara M, Mussini C, Geller JI, Noakes C, Sloma I, Bharathy N, Cairo S, Keller C.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.27237

Bibliografisk träff 2018-08-14

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

Wang Y, Wu L, Yao Y, Lu G, Xu L, Zhou J.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2018.08.007

Bibliografisk träff 2018-02-23

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.

Gohda J, Suzuki K, Liu K, Xie X, Takeuchi H, Inoue JI, Kawaguchi Y, Ishida T.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-018-21942-5

Bibliografisk träff 2017-10-19

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.

Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.21932

Bibliografisk träff 2017-04-18

Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines.

WeiΔ LM, Hugle M, Fulda S.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.17190

Bibliografisk träff 2016-10-25

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N.

Cancer Lett · research-article; journal article · DOI 10.1016/j.canlet.2016.10.025

Bibliografisk träff 2015-10-02

Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.

Wu CP, Hsieh CH, Hsieh CH, Hsiao SH, Luo SY, Su CY, Li YQ, Huang YH, Huang CW, Hsu SC.

Mol Pharm · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.molpharmaceut.5b00312

Bibliografisk träff 2015-01-01

BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.

Bogado RF, Pezuk JA, de Oliveira HF, Tone LG, Brassesco MS.

Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/cad.0000000000000157

Bibliografisk träff 2014-06-09

Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.

Cholewa BD, Pellitteri-Hahn MC, Scarlett CO, Ahmad N.

J Proteome Res · comparative study; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/pr5002516

Bibliografisk träff 2014-04-22

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.

Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC.

Br J Cancer · comparative study; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1038/bjc.2014.195

Bibliografisk träff 2013-12-11

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.

Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin CC, Mahoney J, Modi S, Lee P, Ernstoff MS, Su WC, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA.

Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1002/cncr.28519

Gå till forskningen.

Publikationer i urvalet

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.

Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.

Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies.

BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.

Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis.

<i>In vivo</i> efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts.

Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells.

BI6727, a polo-like kinase 1 inhibitor, synergizes with gefitinib to suppress hepatocellular carcinoma cells via a G2/M arrest mechanism.

Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.

Shedding light on the binding mechanism of kinase inhibitors BI-2536, Volasetib and Ro-3280 with their pharmacological target PLK1.

Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.

Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.

Pharmacological inhibition of PI5P4Kα/β disrupts cell energy metabolism and selectively kills p53-null tumor cells.

α<sub>3</sub> integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer.

Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors.

Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.

BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.

Volasertib suppresses the growth of human hepatocellular carcinoma <i>in vitro</i> and <i>in vivo</i> [Retraction].

Volasertib preclinical activity in high-risk hepatoblastoma.

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.

Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines.

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.

BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.

Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.